Skip to main content
Retour
BMRN logo

BioMarin Pharmaceutical Inc.

Qualité des données : 100%
BMRN
NASDAQ Healthcare Biotechnology
54,09 €
▼ 0,69 € (-1,26%)
Cap. Boursière : 10,40B
Fourchette du Jour
53,36 € 54,37 €
Fourchette 52 Semaines
50,76 € 73,18 €
Volume
1 648 594
Moyenne 50J / 200J
58,63 € / 56,59 €
Clôture Précédente
54,78 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E 29,8 0,3
P/B 1,7 2,9
ROE % 5,9 3,7
Net Margin % 10,8 3,8
Rev Growth 5Y % 14,9 10,0
D/E 0,1 0,2

Objectif de Cours des Analystes

Hold
86,60 € +60.1%
Low: 60,00 € High: 105,00 €
P/E Prévisionnel
12,7
BPA Prévisionnel
4,32 €
Croissance BPA (est.)
+0,0%
CA Est.
3,6 B

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 8,40 €
7,98 € – 8,82 €
5,1 B 6
FY2029 7,57 €
7,19 € – 7,96 €
4,8 B 6
FY2028 6,76 €
4,90 € – 9,01 €
4,4 B 8

Points Clés

Revenue grew 14,93% annually over 5 years — strong growth
Earnings declined -18,26% over the past year
Debt/Equity of 0,11 — conservative balance sheet
Generating 724,96M in free cash flow
Cash machine — converts 207,78% of earnings into free cash flow
Capital efficient — spends only 3,20% of revenue on capex

Croissance

Revenue Growth (5Y)
14,93%
Revenue (1Y)12,87%
Earnings (1Y)-18,26%
FCF Growth (3Y)240,39%

Qualité

Return on Equity
5,94%
ROIC5,95%
Net Margin10,83%
Op. Margin16,56%

Sécurité

Debt / Equity
0,11
Current Ratio5,21
Interest Coverage48,95

Valorisation

P/E Ratio
29,82
P/B Ratio1,71
EV/EBITDA18,25
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 12,87% Revenue Growth (3Y) 15,39%
Earnings Growth (1Y) -18,26% Earnings Growth (3Y) 44,26%
Revenue Growth (5Y) 14,93% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 3,22B Net Income (TTM) 348,90M
ROE 5,94% ROA 4,59%
Gross Margin 77,13% Operating Margin 16,56%
Net Margin 10,83% Free Cash Flow (TTM) 724,96M
ROIC 5,95% FCF Growth (3Y) 240,39%
Safety
Debt / Equity 0,11 Current Ratio 5,21
Interest Coverage 48,95 Dividend Yield 0,00%
Valuation
P/E Ratio 29,82 P/B Ratio 1,71
P/S Ratio 3,23 PEG Ratio -1,71
EV/EBITDA 18,25 Dividend Yield 0,00%
Market Cap 10,40B Enterprise Value 9,73B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 3,22B 2,85B 2,42B 2,10B 1,85B
Net Income 348,90M 426,86M 167,65M 141,56M -64,08M
EPS (Diluted) 1,80 2,21 0,88 0,75 -0,35
Gross Profit 2,48B 2,27B 1,89B 1,59B 1,38B
Operating Income 533,48M 484,21M 185,77M 160,97M -82,34M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 7,59B 6,99B 6,84B 6,38B 6,00B
Total Liabilities 1,51B 1,33B 1,89B 1,77B 1,74B
Shareholders' Equity 6,09B 5,66B 4,95B 4,60B 4,27B
Total Debt 642,87M 649,47M 1,10B 1,09B 1,09B
Cash & Equivalents 1,31B 942,84M 755,13M 724,53M 587,28M
Current Assets 3,95B 3,23B 2,96B 2,75B 2,27B
Current Liabilities 759,03M 606,99M 1,18B 588,88M 546,50M

Scores de Stratégies

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#697 of 1052
37

Activité Récente

Entré Cash Flow Compounder
Mar 24, 2026